REMARKS

Applicant submits the present Rule 1.312 amendment in response to the Notice of Allowance. The present amendment corrects a typographical error in claim 32 whereby the portion added to the claim in this amendment was originally set forth in claim 11 as it existed before the Supplemental Amendment but not introduced into claim 32 as was intended in the Supplemental Amendment. The examiner, Sarah Pihonak, telephoned Applicant's representative on February 4, 2010 indicating that the prior Rule 1.312 amendment filed on January 8, 2010 would not be entered because it amended claim 32 to include the language "or a pharmaceutically acceptable salt thereof." Since claim 1, from which claim 32 depends, also includes this language, it was redundant to also include it in claim 32. Accordingly, Applicant has removed this language from claim 32. The changes shown in this amendment are relative to the claims presented in the Supplemental Amendment filed December 17, 2009.

CONCLUSION

In view of the above remarks, early notification of a favorable consideration is respectfully requested. It is believed that no additional fees are required for entry of these remarks, but should any additional fees be necessary to enter this response, the USPTO is authorized to charge such fees to Deposit Account No. 50-0206.

Respectfully submitted,

Date: 4 Feb 2010

By:

%ober√M. Schulman Registration No. 31, 196

Jeff B. Vockrodt Registration No. 54,833

HUNTON & WILLIAMS LLP Intellectual Property Department 1900 K Street, N.W., Suite 1200 Washington, D.C. 20006-1109 (202) 955-1500 (telephone) (202) 778-2201 (facsimile)